Departments of Pathology,1 Medicine, University of Michigan, Ann Arbor, Michigan 481092
Received 2 November 2005/ Returned for modification 23 December 2005/ Accepted 31 March 2006
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
While members of the TGF-ß superfamily use similar mechanisms to signal to the nucleus, the two major branches achieve specificity by using different elements. Outside the cell, each ligand of the TGF-ß superfamily binds to specific pairs of the receptor serine/threonine kinases, type I and type II (12). There are two distinct modes of the ligand-receptor interaction in the TGF-ß family signaling. One is represented by the members of the BMP subfamily and the other exemplified by TGF-ßs and activins. BMP ligands, such as BMP-2 and BMP-4, exhibit a high affinity for the extracellular ligand binding domains of the type I BMP receptors and a low affinity for the type II receptors. The preassembled type I receptor-ligand complex has a higher binding affinity for the type II receptor (19). In contrast to the BMPs, TGF-ßs and activins display a high affinity for the type II receptors. The ligand binds tightly to the type II receptor first, which allows the subsequent incorporation of the type I receptor, forming a large ligand-receptor complex involving a ligand dimer and four receptor molecules (19).
Within the TGF-ß superfamily, regulation of signaling can occur at multiple levels. The active TGF-ß family ligand is a disulfide-linked homo- or heterodimer that is processed from large inactive precursor proteins. A diverse family of secreted proteins can inhibit TGF-ß superfamily signaling by sequestering ligands away from receptors. In the Golgi complex, processing of the TGF-ß proprotein results in the formation of a latent complex (2, 6). The latency-associated protein LAP1, which is the cleaved amino terminus of the TGF-ß proprotein, together with latent TGF-ß binding protein 1 (LTBP) and the active TGF-ß homodimer constitutes the large latent complex, which associates with the extracellular matrix and can be released and activated by proteolytic cleavage. Extracellular inhibitors of BMP signaling include vertebrate Chordin, which binds directly to BMPs through the cysteine-rich (CR) domains containing CXXCXC and CCXXC motifs (5, 10, 19). While Chordin blocks BMP/receptor interactions, the CR domain protein KCP enhances BMP/receptor interactions to increase the efficacy of signaling (11). Similarly, the CR domain protein connective tissue growth factor (CTGF) also enhances TGF-ß-mediated signaling while suppressing the BMP-dependent pathway (1).
The KCP protein contains 18 cysteine-rich domains and is expressed in the developing kidney at both early and late stages (11). KCP expression corresponds to the formation of epithelial structures within the intermediate mesoderm and to the formation of the proximal tubules in the more developed metanephric kidney. Unlike Chordin or CTGF, KCP enhances BMP-mediated signaling in a paracrine manner by interacting with the type I receptor to facilitate the binding of BMP7 to BMP receptor 1A (11). Mice homozygous for a mutant KCP allele show no gross developmental abnormalities but exhibit enhanced susceptibility to developing renal interstitial fibrosis, a process known to be regulated both by BMPs and by TGF-ß, in two different animal models (11).
In this report, we characterized the effects of the CR domain protein KCP on TGF-ß- and activin-mediated signaling. By use of Smad2/3-dependent reporter assays, KCP is able to suppress activin- and TGF-ß-dependent transcription and Smad phosphorylation. KCP purified from conditioned media can interact directly with either activin or TGF-ß1. Furthermore, expression of KCP in MDCK cells enhances the formation of tubules in response to hepatocyte growth factor and inhibits the negative effects of activin A in vitro. These data indicate a suppressor function for KCP in the regulation of TGF-ß superfamily signaling. The ability to enhance BMP-mediated signaling while suppressing TGF-ß/activin-mediated signaling may have important consequences in the progression of renal disease and may underlie the profibrotic phenotype found in KCP mutants.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Luciferase reporter assays. NIH 3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum and 100 U/ml penicillin and streptomycin under conditions of humidified 5% CO2 and 95% air at 37°C. Cells were transfected using FuGene 6 as described in the manufacturer's protocol (Roche Molecular Biochemicals). Cells were harvested 48 h after transfection. NIH 3T3 parental and KCP stably transfected cells were cotransfected with 3TP-Lux plasmid and ß-galactosidase plasmid, used to monitor transfection efficiency. Activin A or TGF-ß1 (R&D Systems) was added into the media at indicated concentrations 24 h after transfection. Cells were harvested, luciferase activity was measured by using a luciferase assay system (Promega), and luciferase value was normalized to ß-galactosidase activity. The luciferase value under the condition without any stimulation was expressed as 1; the other values that represented the responses to activin A or TGF-ß1 were divided by the basic value and expressed as increasing amounts (n-fold). Each experiment was repeated three times, and the results are presented as averages ± 1 standard deviation from the mean.
Collection of the conditioned media of KCP stable cells. The KCP stably transfected cells were grown to confluence in DMEM with 10% fetal bovine serum and Geneticin or zeocin. The monolayer was washed with phosphate-buffered saline (PBS), and the medium was changed to serum-free DMEM with 1x insulin-transferrin-selenium-X (Invitrogen) for another 48 h. The conditioned medium was harvested and centrifuged to remove the cell debris. The clarified medium was concentrated about 10-fold by using an Amicon Ultra-15 NMWL 100K centrifugal filter device with a membrane at the speed of 3,100 rpm for 20 min, as described in the manufacturer's protocol (Millipore), and stored at 70°C. Control medium was collected in parallel from NIH 3T3 parental cells.
Western blot analysis. Western blot analysis was performed with equal amounts of protein obtained by lysis of cells in 1% NP lysis buffer (15 mM sodium chloride, 1% NP-40, 50 mM Tris [pH 8.0]) and a mixture of protease inhibitors (Roche Molecular Biochemicals). The lysates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted with antibodies as indicated. Horseradish peroxidase-conjugated secondary antibodies were used to detect antigen-antibody complexes by an ECL detection system (Amersham Biosciences). The antibodies used were anti-Myc (9E10, 1:2,000; BabCO), anti-phosphorylated Smad2 Ser 465/467 (1:1,000; Cell Signaling), anti-Smad2 (1:1,000; Santa Cruz), anti-activin A (1:500; R&D Systems), anti-TGF-ß1 (1:500; R&D Systems), antitubulin (1:10,000; Sigma), and anti-activated caspase-3 (1:500; Cell Signaling Technology).
For quantitation of Western blots, either 60 µg (total Smad2) or 120 µg (phosphorylated Smad2 [P-Smad2]) of total kidney protein lysates was fractionated on 8% polyacrylamide gels and transferred to a polyvinylidene difluoride membrane. Enhanced chemiluminescence reagents were used to visualize the secondary antibody, with attention paid to ensure that the film was not saturated. Images were scanned from the film with an Agfa Arcus II scanner, and band density quantification was performed by using Multi-Analyst software (Bio-Rad Laboratories). Results were expressed as means ± standard errors. Statistical analysis was carried out by unpaired Student's t test. Differences with P values of <0.05 were considered significant.
Pull-down assays. For biotinylation, cells were grown to confluence, washed in PBS, and incubated with 0.5 mg/ml of N-hydroxysulfosuccinimide-biotin (Pierce) at 4°C for 20 min. After being quenched with 50 mM ammonium chloride, cells were washed in PBS, and lysates were prepared in 1% NP-40 lysis buffer. Protein complexes were pulled down with neutravidin agarose, washed three times in PBS, and incubated with 100 ng of TGF-ß1 or activin A (R&D Systems) in a total volume of 200 ml PBS at 4°C overnight. After three more washing steps, proteins were boiled in 2x SDS-PAGE buffer and analyzed on 12% gels.
For nickel affinity pull-downs, the concentrated conditioned media of parental and His-tagged KCP stably expressing cells were run through ProBond Ni-nitrilotriacetic acid agarose resin (QIAGEN) and washed under native conditions according to the manufacturer's protocol. The beads were washed with PBS, incubated with 0.5 ng/µl of TGF-ß1 or 5 ng/µl of activin A in PBS containing 1.0 mM Mg2+ and 1.3 mM Ca2+ overnight, and then washed with PBS three times and eluted in 2x SDS-PAGE sample buffer. The Ni bead pull-down fraction was detected by Western blotting.
Isolation and analysis of primary kidney cells. Proximal tubule cells were isolated by collagenase digestion, sieving, and use of Percoll gradients as originally described by Humes et al. (7). A defined serum-free medium was used as described by Sens et al. (18). Cells were expanded and frozen in aliquots. Samples were thawed in six-well plates and used for testing TGF-ß responsiveness without any additional passages. For immunostaining, cells were fixed for 10 min in 4% paraformaldehyde, washed twice in PBS and 0.1% Tween 20, and stained with anti-E-cadherin (Cell Signaling Technologies) and Cy3-conjugated anti-smooth muscle actin (SMA) monoclonal antibody (Sigma).
Animal models of renal injury. For the induction of acute tubular necrosis (ATN), age-matched mice were injected intraperitoneally with 250 mg folic acid/kg of body weight (8) and sacrificed at 7, 14, and 28 days postinjury. Mice were observed daily after injection, and serum was collected at the time of death. At least seven animals of each genotype were analyzed at each time point. KCP null animals were defined as described previously (11).
For the induction of renal fibrosis, the unilateral urethral obstruction (UUO) model was utilized. Mice were anesthetized by intraperitoneal injection of ketamine and xylazine. Through a midline abdominal incision, the right ureter was exposed and tied off at the midurethral level with fine suture materials (4-0 silk) to induce a complete obstruction. Mice were allowed to recover from anesthesia and were kept with an ad libitum supply of food and water until the indicated time of sacrifice (7, 13, and 28 days). At least four mice of wild-type and KCP null genotypes were analyzed at each time point. Both obstructed and contralateral kidneys were harvested for protein analysis.
| RESULTS |
|---|
|
|
|---|
|
The suppressed response to activin A or TGF-ß1 in KCP-expressing cells was further confirmed by Western blotting with antibodies specific for P-Smad2/3 serine 465/467 (Fig. 2). By use of stably expressing KCP and parental 3T3 cells, whole-cell lysates were prepared 1 h after increasing amounts of TGF-ß1 or activin A were added. With increasing amounts of TGF-ß1, the KCP-expressing cells still responded, although there was little increase at higher concentrations and the overall levels of P-Smad2/3 were decreased compared to levels for the parental line (Fig. 2A). With increasing amounts of activin A, there was little induction of P-Smad2/3 in KCP-expressing cells even at high concentrations (Fig. 2B). To exclude any variations due to selection of stably expressing clones, we transfected KCP transiently into HEK293 cells and added TGF-ß1 or activin 48 h posttransfection (Fig. 2C). For these transient experiments, we utilized the Sec-Tag vector containing an immunoglobulin
leader sequence to improve secretion. Cells expressing Sec-Tag KCP showed a marked reduction of P-Smad2/3 upon addition of either TGF-ß1 or activin A compared to control cells. Duplicate blots were probed for total Smad2 protein to reveal nearly equal amounts in all lysates.
|
The KCP protein contains multiple cysteine-rich domains that can bind directly to ligands of the TGF-ß superfamily. Thus, we tested for direct physical interactions between KCP and TGF-ß1 or activin A by using biotinylated KCP or poly-His-tagged KCP from conditioned media (Fig. 3). Total extracellular proteins from KCP-expressing cell lines and control cells were biotinylated and used to capture recombinant TGF-ß1 (Fig. 3A). Biotinylated proteins from KCP-expressing cells, but not from control cells, were able to pull down TGF-ß by use of neutravidin beads. Furthermore, an independent method utilized poly-His-tagged KCP protein, and ligands were captured on nickel affinity beads. In these assays, both recombinant TGF-ß1 (Fig. 3B) and activin A (Fig. 3C) were able to interact with the His-tagged KCP protein, as evidenced by the coprecipitation with nickel agarose. Thus, the data suggest a physical interaction between these ligands and KCP or with another KCP-associated protein. This interaction could act to attenuate the signaling responses observed with the Smad2/3 reporter by partially sequestering ligands from their receptors.
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
KCP is not the first extracellular CR domain protein that can differentially regulate the TGF-ß superfamily. Initial characterization of the prototype CR proteins Chordin and Short gastrulation (Sog) revealed inhibition of BMP and Decapentaplegic (Dpp) signaling during axis formation in frogs and flies, respectively. More recently, however, sog was shown to limit dpp activity, in cooperation with twisted gastrulation, and to allow diffusion of a latent complex that can be activated by tolloid (4, 20, 21). These modifiers thus transform a gradient of ligand into a stepwise response with a distinct boundary of Smad activation. CTGF, another CR domain protein, also has dual roles in regulating the TGF-ß family members. Similarly to KCP, the CTGF protein binds to both BMPs and TGF-ßs (1), but its effect on signaling is opposite that of KCP in that it inhibits BMP-mediated signaling while enhancing the TGF-ß response. Thus, CR domain proteins are not exclusive inhibitors but are able to both positively and negatively modulate the signals received from different branches of the TGF-ß superfamily of ligands to achieve a balance of outputs.
The mechanism of TGF-ß and activin inhibition remains to be clearly defined. While KCP binds to BMPs and can enhance the interaction of BMPs with the type I receptor, we have not been able to assay the effects of KCP on the TGF-ß receptors for several technical reasons. Given the size and cysteine-rich nature of KCP, it has not been possible to make a soluble recombinant form of the protein in bacteria, thus precluding any quantitative biochemical studies in vitro. However, we have been able to show binding of KCP to TGF-ß and activin in conditioned media, though it is possible that this interaction may be mediated by other proteins. Whether the interaction of KCP with these two ligands prevents receptor-ligand interactions remains to be determined. Given the size and complexity of KCP, sequestration of ligands from the receptor complex certainly is a possibility that needs to be addressed.
Mice homozygous for a targeted allele of KCP show no gross developmental defects but are sensitive to developing renal fibrotic disease (11). Renal fibrosis is due to an increase in interstitial fibroblasts and increased deposition of basement membrane components. Currently, TGF-ß1 is regarded as the predominant profibrotic stimulus in the kidney and many other tissues (3, 17, 22). Consistent with this hypothesis, deletion of the downstream effector Smad3 protects against fibrotic disease in the kidney after obstruction (15). TGF-ß1 induces cell hypertrophy in the early phase of fibrotic disease and may promote epithelial cell-to-mesenchyme transition and apoptosis in later stages of fibrotic diseases (9). It appears that BMP-7 counteracts this TGF-ß1-driven fibrotic response (13, 23, 24). Though KCP expression in adult tissues is undetectable, we have observed the induction of KCP expression in renal fibrosis and renal injury models (11). Furthermore, KCP mutants show decreased levels of P-Smad1 after injury, indicating a decrease in BMP responsiveness. This alone may underlie the increased sensitivity to developing renal fibrosis. However, the potential for KCP mutants to have increased TGF-ß responses, due to the absence of KCP-mediated inhibition, may also contribute to the phenotype. The increased P-Smad2 levels observed with both the ATN and the UUO model are consistent with this hypothesis, though the increased P-Samd2 levels are significantly less than the decreased P-Smad1 levels observed with KCP null kidneys. Nevertheless, the increased sensitivity of KCP mutants to developing renal fibrotic disease may be due to a combination of decreased BMP signaling and increased TGF-ß signaling. Given the importance of TGF-ßs and BMPs in mediation of injury, repair, and fibrosis, the potential role for KCP to affect these processes clearly merits further investigation.
The roles of TGF-ß in renal injury are likely to be complex. In addition to stimulating epithelial cell-to-mesenchyme transition, TGF-ß can promote cell death in vitro and in vivo (16). Activation of caspase-3 by low doses of TGF-ß in primary renal epithelial cells from KCP mutant mice suggests that apoptosis is an important component of the stress response to either obstruction or acute tubular necrosis. Indeed, we have observed significant differences in mortality after folic acid induction of ATN in KCP null mice compared to mortality in wild-type mice (11), suggesting that the initial amount of cell death may be increased.
In summary, KCP is the first enhancer of BMP signaling described to date that suppresses TGF-ß and activin signaling and as such may play an important role in mediating the signal specificity between competing inputs in the initiation and progression of renal disease.
| ACKNOWLEDGMENTS |
|---|
This work is supported by NIH grants DK062914 to G.R.D and DK002803 to S.R.P.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Annes, J. P., J. S. Munger, and D. B. Rifkin. 2003. Making sense of latent TGFbeta activation. J. Cell Sci. 116:217-224.
3. Chatziantoniou, C., and J. C. Dussaule. 2005. Insights into the mechanisms of renal fibrosis: is it possible to achieve regression? Am. J. Physiol. Renal Physiol. 289:F227-F234.
4. Eldar, A., R. Dorfman, D. Weiss, H. Ashe, B. Z. Shilo, and N. Barkai. 2002. Robustness of the BMP morphogen gradient in Drosophila embryonic patterning. Nature 419:304-308.[CrossRef][Medline]
5. Garcia Abreu, J., C. Coffinier, J. Larrain, M. Oelgeschlager, and E. M. De Robertis. 2002. Chordin-like CR domains and the regulation of evolutionarily conserved extracellular signaling systems. Gene 287:39-47.[Medline]
6. Gumienny, T. L., and R. W. Padgett. 2002. The other side of TGF-beta superfamily signal regulation: thinking outside the cell. Trends Endocrinol. Metab. 13:295-299.[CrossRef][Medline]
7. Humes, H. D., W. H. Fissell, W. F. Weitzel, D. A. Buffington, A. J. Westover, S. M. MacKay, and J. M. Gutierrez. 2002. Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am. J. Kidney Dis. 39:1078-1087.[CrossRef]
8. Imgrund, M., E. Grone, H. J. Grone, M. Kretzler, L. Holzman, D. Schlondorff, and U. W. Rothenpieler. 1999. Re-expression of the developmental gene Pax-2 during experimental acute tubular necrosis in mice 1. Kidney Int. 56:1423-1431.[CrossRef][Medline]
9. Kalluri, R., and E. G. Neilson. 2003. Epithelial-mesenchymal transition and its implications for fibrosis. J. Clin. Investig. 112:1776-1784.[CrossRef][Medline]
10. Larrain, J., D. Bachiller, B. Lu, E. Agius, S. Piccolo, and E. M. De Robertis. 2000. BMP-binding modules in chordin: a model for signalling regulation in the extracellular space. Development 127:821-830.[Abstract]
11. Lin, J., S. R. Patel, X. Cheng, E. A. Cho, I. Levitan, M. Ullenbruch, S. H. Phan, J. M. Park, and G. R. Dressler. 2005. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 11:387-393.[CrossRef][Medline]
12. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
13. Patel, S. R., and G. R. Dressler. 2005. BMP7 signaling in renal development and disease. Trends Mol. Med. 11:512-518.[Medline]
14. Piek, E., W. J. Ju, J. Heyer, D. Escalante-Alcalde, C. L. Stewart, M. Weinstein, C. Deng, R. Kucherlapati, E. P. Bottinger, and A. B. Roberts. 2001. Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276:19945-19953.
15. Sato, M., Y. Muragaki, S. Saika, A. B. Roberts, and A. Ooshima. 2003. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Investig. 112:1486-1494.[CrossRef][Medline]
16. Schiffer, M., M. Bitzer, I. S. Roberts, J. B. Kopp, P. ten Dijke, P. Mundel, and E. P. Bottinger. 2001. Apoptosis in podocytes induced by TGF-beta and Smad7. J. Clin. Investig. 108:807-816.[CrossRef][Medline]
17. Schnaper, H. W., T. Hayashida, S. C. Hubchak, and A. C. Poncelet. 2003. TGF-beta signal transduction and mesangial cell fibrogenesis. Am. J. Physiol. Renal Physiol. 284:F243-F252.
18. Sens, D. A., C. J. Detrisac, M. A. Sens, M. R. Rossi, S. L. Wenger, and J. H. Todd. 1999. Tissue culture of human renal epithelial cells using a defined serum-free growth formulation. Exp. Nephrol. 7:344-352.[CrossRef][Medline]
19. Shi, Y., and J. Massague. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700.[CrossRef][Medline]
20. Shimmi, O., and M. B. O'Connor. 2003. Physical properties of Tld, Sog, Tsg and Dpp protein interactions are predicted to help create a sharp boundary in Bmp signals during dorsoventral patterning of the Drosophila embryo. Development 130:4673-4682.
21. Sutherland, D. J., M. Li, X. Q. Liu, R. Stefancsik, and L. A. Raftery. 2003. Stepwise formation of a SMAD activity gradient during dorsal-ventral patterning of the Drosophila embryo. Development 130:5705-5716.
22. Tamaki, K., and S. Okuda. 2003. Role of TGF-beta in the progression of renal fibrosis. Contrib. Nephrol. 139:44-65.[Medline]
23. Zeisberg, M., J. Hanai, H. Sugimoto, T. Mammoto, D. Charytan, F. Strutz, and R. Kalluri. 2003. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9:964-968.[CrossRef][Medline]
24. Zeisberg, M., A. A. Shah, and R. Kalluri. 2005. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280:8094-8100.
25. Zwijsen, A., K. Verschueren, and D. Huylebroeck. 2003. New intracellular components of bone morphogenetic protein/Smad signaling cascades. FEBS Lett. 546:133-139.[CrossRef][Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|